Table 3. 16 IHC markers and OS in the biomarker population.

		OS (months)		P value		Pinteraction
		Sunitinib	Sorafenib	Sunitinib	Sorafenib
HIF-1α	High	29.2	32.5	0.849 (1.073, 0.521–2.209)	0.921 (0.965. 0.473–1.968)	0.737
			Low	36.5	38.5
HIF-2α	High	37	27.2	0.047 (0.474, 0.227–0.989)	0.310 (1.434, 0.715–2.877)	0.011
			Low	20	40
CAIX	High	49	31.5	0.038 (0.461, 0.221–0.958)	0.260 (1.536, 0.728–3.244)	0.027
			Low	21	31
VEGF	High	36.5	55	0.248 (0.652, 0.315–1.348)	0.024 (0.368, 0.154–0.879)	0.215
			Low	32.1	25.8
VEGFR1	High	36.5	49	0.282 (0.672, 0.325–1.386)	0.103 (0.531, 0.249–1.136)	0.243
			Low	29.6	29.1
VEGFR2	High	36.5	42	0.897 (0.950, 0.435,2.073)	0.515 (1.308, 0.582–2.940)	0.138
			Low	24.8	31.5
VEGFR3	High	29.4	28.15	0.989 (1.005, 0.478–2.114)	0.765 (1.119, 0.535–2.341)	0.127
			Low	33.25	37
PDGFB	High	36.5	37	0.373 (0.829, 0.352–1.912)	0.490 (1.343, 0.581–3.105)	0.121
			Low	27.6	35
PDGFRB	High	29.7	49	0.457 (1.314, 0.640–2.696)	0.333 (0.700, 0.340–1.441)	0.130
			Low	32.1	31.1
CD31	High	40.1	36.5	0.093 (0.529, 0.252–1.112)	0.921 (0.965, 0.473–1.968)	0.037
			Low	24.65	33
CD44	High	24.8	36	0.033 (2.380, 1.071–5.289)	0.476 (1.302, 0.630–2.691)	0.562
			Low	52	49
bcl-xL	High	21	36.5	0.011 (2.626, 1.244–5.543)	0.477 (0.772, 0.377–1.577)	0.465
			Low	49	36
KIT	High	49	19.15	0.7140 (0.835, 0.324–1.334)	0.508 (1.280, 0.616–2.660)	0.622
			Low	28.4	37
p21	High	29.2	31	0.185 (1.690, 0.778–3.671)	0.276 (1.494, 0.726–3.075)	0.600
			Low	40.1	46
RET	High	28.05	25.2	0.236 (1.610, 0.732–3.540)	0.039 (2.377, 1.044–5.411)	0.452
			Low	32.1	49
FLT-3	High	36.5	42	0.867 (0.939, 0.447–1.970)	0.600 (0.828, 0.410–1.676)	0.564
			Low	29.4	30.6

Survival data are median, p values and HRs for sunitinib- and sorafenib-treated groups are both come from multivariable analysis, they compare higher biomarker group to lower biomarker group; p_interaction values are come from multivariate analysis (Cox model analysis) to assess the potential differential effects of immunostainings between the two treatment groups.